Fingerprint
Dive into the research topics of 'Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Mayo Phase Consortium
Research output: Contribution to journal › Article › peer-review
123
Scopus
citations